RT Journal Article
SR Electronic
T1 Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.113.120618
DO 10.2967/jnumed.113.120618
A1 Keith A. Johnson
A1 Satoshi Minoshima
A1 Nicolaas I. Bohnen
A1 Kevin J. Donohoe
A1 Norman L. Foster
A1 Peter Herscovitch
A1 Jason H. Karlawish
A1 Christopher C. Rowe
A1 Maria C. Carrillo
A1 Dean M. Hartley
A1 Saima Hedrick
A1 Virginia Pappas
A1 William H. Thies
YR 2013
UL http://jnm.snmjournals.org/content/early/2013/01/28/jnumed.113.120618.abstract
AB Positron emission tomography (PET) of brain amyloid β is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated, and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes.